| Oxford University, Ph.D. |
Dr. Jeffrey P. Whitten brings to CalciMedica more than twenty-five years of experience in the pharmaceutical and biotechnology industries. Previously, he served as Vice President of Research at Cylene, Director of Chemistry at Neurocrine, Group Leader at Marion Merrell Dow (now Aventis) and as a chemist at Glaxo Pharmaceuticals and Sandoz (now Novartis). He has been responsible for the discovery and development of numerous clinical candidates for a variety of diseases and has also worked on the teams that brought Allegra and Albutamol to the market.
